| Field | Value |
|-------|-------|
| NCT Number | NCT05820425 |
| Status | Recruiting |
| Phase | Not Applicable |
| Sponsor | University Hospital, Grenoble |
| Study Type | Observational |
| Conditions | Parkinson's Disease |
| Outcome Measures | Local field potential recordings from subthalamic nucleus |
Local field potentials (LFPs) represent the summed electrical activity of neuronal populations surrounding the recording electrode. In Parkinson's disease (PD), the subthalamic nucleus (STN) has emerged as a critical structure for understanding the neurophysiological basis of motor symptoms and for optimizing therapeutic interventions such as deep brain stimulation (DBS). The STN serves as a central hub within the basal ganglia circuitry, integrating excitatory glutamatergic inputs from the cortex and globus pallidus externus (GPe), and project[ing] to the globus pallidus internus (GPi) and substantia nigra pars reticulata (SNr)[@brown2003].
The significance of STN LFP recordings in PD extends beyond basic neuroscience. Pathological oscillatory patterns—particularly excessive beta band (13-35 Hz) activity—have been consistently documented in PD patients and correlate with clinical motor impairment[@kuhn2006]. This oscillatory pathology represents a dysfunction in the normal communication within basal ganglia-thalamocortical networks, and its modulation through therapeutic interventions forms the rationale for adaptive DBS approaches.
The subthalamic nucleus (STN) is a key node in the basal ganglia circuitry and a primary target for deep brain stimulation (DBS) in Parkinson's disease. The STN plays a critical role in motor control, receiving inputs from the motor cortex via the hyperdirect pathway and integrating information with indirect pathway signals from the striatum through the GPe. Under normal conditions, the STN helps coordinate movement execution and motor learning. However, in PD, the STN becomes hyperactive and exhibits pathological firing patterns that contribute to(brady)kinesia and rigidity[@marsden2001].
The degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc) leads to excessive inhibition of the external segment of the globus pallidus (GPe), which in turn disinhibits the STN. This results in increased excitatory output from the STN to the GPi and SNr, ultimately producing excessive inhibition of the thalamocortical system and reduced motor output. Understanding these circuit-level changes has been crucial for developing STN-DBS as an effective treatment for advanced PD.
The most well-characterized neurophysiological abnormality in PD is the excessive synchronization of neuronal activity in the beta frequency band (13-35 Hz)[@kuhn2006]. This pathological beta activity is observed throughout the basal ganglia in PD patients, with particularly robust findings in the STN. The significance of beta oscillations in PD includes:
Motor Impairment Correlation: Beta-band power in the STN correlates positively with bradykinesia and rigidity scores on the Unified Parkinson's Disease Rating Scale (UPRS) motor section. Patients with higher baseline beta activity tend to have more severe motor symptoms[@kuhn2006; @nicholson2022].
Dopamine Responsiveness: Dopaminergic medications reduce STN beta power, and this reduction correlates with clinical improvement following levodopa administration[@boon2020]. This suggests that beta oscillations serve as a biomarker for dopaminergic tone in the basal ganglia.
Freezing of Gait: Elevated beta activity in the STN has been specifically linked to freezing of gait (FOG), one of the most disabling PD symptoms that responds poorly to conventional therapies. Specific patterns of beta synchronization may predict FOG episodes[@frankemolte2019].
Cognitive Correlations: Interestingly, STN beta activity also correlates with certain cognitive deficits in PD, particularly executive dysfunction and working memory impairments. This suggests that beta oscillations may reflect broader network dysfunction beyond pure motor circuits[@swann2016].
This study aims to characterize the local field potential signatures of the subthalamic nucleus in PD patients, potentially providing insights into:
Under normal conditions, the STN exhibits heterogeneous neuronal activity with a mix of regular firing patterns and irregular bursting. The firing rate of STN neurons in healthy individuals ranges from 25-45 Hz on average, with significant inter-individual variability. Importantly, STN neurons in the healthy state show minimal synchronization in the beta band, reflecting the balanced excitation and inhibition that characterizes normal basal ganglia function.
In Parkinson's disease, several distinct changes characterize STN activity:
Beta Synchronization: As described above, the most prominent finding is increased beta-band synchronization. This manifests as increased beta-band power in the LFP and as coherent beta activity between STN neurons and between the STN and other basal ganglia nodes[@kuhn2008].
Firing Rate Changes: STN neurons show increased firing rates in PD compared to healthy controls, though this change is less consistent than the synchronization findings.
Bursting Patterns: STN neurons in PD exhibit more frequent and prolonged bursting activity, which may reflect impaired synaptic integration and reduced dopaminergic modulation.
Gamma Activity: While gamma activity (>60 Hz) is typically reduced in PD, some studies have identified pathological high-frequency oscillations that may correlate with dyskinesIAS[@velmurugan2021].
A key finding in PD neurophysiology is the reciprocal relationship between beta and gamma activity. Increasing gamma activity (through movement or dopaminergic medication) is associated with decreased beta activity, and vice versa. This beta-gamma antagonism suggests competing neural representations—beta reflecting the "idle" or "resting" motor network state, while gamma reflects active movement processing. Therapeutic interventions that enhance gamma or suppress beta may therefore produce similar clinical benefits through different mechanisms.
Intraoperative LFP recordings in the STN are typically performed using:
Local field potentials will be analyzed for:
STN LFPs represent a promising biomarker for several clinical applications:
Intraoperative Mapping: LFP recordings help identify the optimal electrode trajectory and contact position within the STN, potentially improving surgical outcomes.
Postoperative Programming: Beta power measurements can guide initial DBS parameter selection and titr:[ation](url), though this application remains investigational.
Disease Monitoring: Longitudinal LFP recordings could potentially track disease progression or treatment response over time.
The correlation between STN beta activity and motor symptoms provides a neurophysiological window into the basal ganglia dysfunction underlying PD. Studies have demonstrated:
Understanding STN LFP abnormalities has direct implications for therapy development:
Adaptive DBS: Closed-loop systems that suppress beta activity when detected could reduce side effects and improve efficacy[@little2013].
Targeted Pharmacotherapy: Drugs that reduce beta synchronization without causing dyskinesIAS might provide non-invasive alternatives to DBS.
Network Surgery: Understanding the network consequences of STN lesions or stimulation guides surgical target selection.
The primary risks associated with STN LFP recording during DBS surgery include:
The study implements standard neurosurgical safety protocols including:
The STN occupies a central position in the basal ganglia indirect pathway. Understanding STN LFPs requires context:
The therapeutic implications of beta-gamma antagonism include:
STN LFPs should be considered alongside other PD biomarkers:
| Biomarker | Advantages | Limitations |
|----------|-------------|--------------|
| STN LFP | Direct measurement of basal ganglia activity | Invasive, requires surgery |
| DAT imaging | Non-invasive dopamine terminal assessment | Radiation exposure |
| Motor cortex EEG | Non-invasive, correlates with STN activity | Lower spatial resolution |
| FDG-PET | Metabolic networks | Limited temporal resolution |
Studies in non-human primates have provided crucial insights into STN physiology and have been largely confirmed in human studies, suggesting good translational validity for the STN LFP biomarker approach.
STN LFP recordings inform several emerging therapeutic approaches:
Adaptive DBS: Real-time beta detection to modulate stimulation intensity Multi-target Systems: Coordinated stimulation of STN and other targets Closed-loop Pharmacotherapy: LFP-guided drug delivery
Further development of LFP biomarkers includes:
Wearable Systems: Implantable devices for chronic LFP monitoring Surface Alternatives: Non-invasive correlates of subcortical LFPs Machine Learning: Pattern recognition for improved biomarker specificity